These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25083818)

  • 1. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
    Bam R; Venkateshaiah SU; Khan S; Ling W; Randal SS; Li X; Zhang Q; van Rhee F; Barlogie B; Epstein J; Yaccoby S
    Blood Cancer J; 2014 Aug; 4(8):e234. PubMed ID: 25083818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
    Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase: potential target in human multiple myeloma.
    Liu Y; Dong Y; Jiang QL; Zhang B; Hu AM
    Leuk Lymphoma; 2014 Jan; 55(1):177-81. PubMed ID: 23581641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
    Yang Y; Shi J; Gu Z; Salama ME; Das S; Wendlandt E; Xu H; Huang J; Tao Y; Hao M; Franqui R; Levasseur D; Janz S; Tricot G; Zhan F
    Cancer Res; 2015 Feb; 75(3):594-604. PubMed ID: 25589346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
    Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
    Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
    Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
    Von Suskil M; Sultana KN; Elbezanti WO; Al-Odat OS; Chitren R; Tiwari AK; Challagundla KB; Srivastava SK; Jonnalagadda SC; Budak-Alpdogan T; Pandey MK
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase: oncotarget in myeloma.
    Tai YT; Anderson KC
    Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.
    Ma N; Pang H; Shen W; Zhang F; Cui Z; Wang J; Wang J; Liu L; Zhang H
    Int J Mol Med; 2015 Feb; 35(2):425-32. PubMed ID: 25504108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
    Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
    Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
    Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
    Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular maturation defects in Bruton's tyrosine kinase-deficient immature B cells are amplified by premature B cell receptor expression and reduced by receptor editing.
    Middendorp S; Hendriks RW
    J Immunol; 2004 Feb; 172(3):1371-9. PubMed ID: 14734712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I.
    Sacristán C; Tussié-Luna MI; Logan SM; Roy AL
    J Biol Chem; 2004 Feb; 279(8):7147-58. PubMed ID: 14623887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.
    Himmelmann A; Thevenin C; Harrison K; Kehrl JH
    Blood; 1996 Feb; 87(3):1036-44. PubMed ID: 8562928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis.
    Pandey MK; Gowda K; Sung SS; Abraham T; Budak-Alpdogan T; Talamo G; Dovat S; Amin S
    Exp Hematol; 2017 Sep; 53():31-42. PubMed ID: 28647392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.
    Middendorp S; Dingjan GM; Maas A; Dahlenborg K; Hendriks RW
    J Immunol; 2003 Dec; 171(11):5988-96. PubMed ID: 14634110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice.
    Middendorp S; Dingjan GM; Hendriks RW
    J Immunol; 2002 Mar; 168(6):2695-703. PubMed ID: 11884435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma.
    Yue C; Niu M; Shan QQ; Zhou T; Tu Y; Xie P; Hua L; Yu R; Liu X
    J Exp Clin Cancer Res; 2017 Sep; 36(1):132. PubMed ID: 28946903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.